Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease

References

• Johns Hopkins University & Medicine. COVID-19 map. [ cited 2020 Aug 26]. Available from: https://coronavirus.jhu.edu/map.html
   Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. Published2020:323(18);1824-1836.
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig. 2020;130(5):2620–2629.
   PubMed Web of Science ®Google Scholar
• Picchianti Diamanti A, Rosado MM, Pioli C, et al. Cytokine release syndrome in COVID-19 patients, A new scenario for an old concern: the fragile balance between infections and autoimmunity. IJMS. 2020;21(9):3330.
   Google Scholar
• Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.
   PubMed Web of Science ®Google Scholar
• Yale School of Medicine. COVID-19 treatment adult algorithm. [ Published 2020 Apr 27; cited 2020 May 17]. Available from: https://files-profile.medicine.yale.edu/documents/e91b4e5c-ae56-4bf1-8d5f-e674b6450847
   Google Scholar
• Bridgham and Women’s Hospital. Brigham and women’s hospital COVID-19 clinical guidelines. [cited 2020 May 17]. Available from: https://covidprotocols.org/
   Google Scholar
• ClinicalTrials.gov. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19. [ Published 2020 Apr 6; cited 2020 May 17]. Available from https://clinicaltrials.gov/ct2/show/NCT04315298
   Google Scholar
• The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. Published online 2020 July 17:NEJMoa2021436.
   Web of Science ®Google Scholar
• Actemra® (tocilizumab). Published online 2017.
   Google Scholar
• Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010;50(7):754–766.
   PubMed Web of Science ®Google Scholar
• Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124–e131.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25–224ra25.
   PubMed Web of Science ®Google Scholar
• Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139–303ra139.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154–5157.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62.
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970–10975.
   PubMed Web of Science ®Google Scholar
• Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID‐19: A single center experience. J Med Virol. 2020;92(7):814–818.
   PubMed Web of Science ®Google Scholar
• Eimer J, Vesterbacka J, Svensson A-K, et al. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study. J Intern Med. Published online 2020 Aug 3.
   PubMed Web of Science ®Google Scholar
• Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients. Chest. 2020 Oct;158(4)1397-1408.
   Web of Science ®Google Scholar
• Biran N, Ip A, Ahn J, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020;2(10):e603–e612.
   PubMedGoogle Scholar
• Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8):e474-e484.
   Google Scholar
• Potere N, Di Nisio M, Rizzo G, et al. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation. Int J Infect Dis. Published online 2020 Aug 5;100:421–424.
   PubMed Web of Science ®Google Scholar
• Roche. Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. [cited 2020 Jul 29]. Available from: https://www.roche.com/investors/updates/inv-update-2020-07-29.htm
   Google Scholar
• Rosas I, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv. Published online 2020 Jan 1.
   Google Scholar
• Kevzara® (sarilumab). Published online 2017.
   Google Scholar
• Xu C, Su Y, Paccaly A, et al. Population pharmacokinetics of sarilumab in patients with rheumatoid arthritis. Clin Pharmacokinet. 2019;58(11):1455–1467.
   PubMed Web of Science ®Google Scholar
• Emery P, Rondon J, Parrino J, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology. 2019;58(5):849–858.
   PubMed Web of Science ®Google Scholar
• Ishii T, Sato Y, Munakata Y, et al. AB0472 Pharmacodynamic effect and safety of single-dose sarilumab sc or tocilizumab iv or sc in patients with rheumatoid arthritis (RA). In Rheumatoid arthritis – biological DMARDs BMJ Publishing Group Ltd and European League Against Rheumatism; 2018. p 1397–1398.
   Google Scholar
• Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. TCRM. 2019;15:323–335.
   Google Scholar
• Benucci M, Giannasi G, Cecchini P, et al. COVID‐19 pneumonia treated with Sarilumab: A clinical series of eight patients. J Med Virol. Published online 2020 June 16;jmv.26062.
   Google Scholar
• Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020;;79:1277-1285.
   Web of Science ®Google Scholar
• Gremese E, Cingolani A, Bosello SL, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine. Published online 2020 Oct;100553.
   PubMedGoogle Scholar
• Sanofi, Regeneron. Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients. [cited 2020 Aug 26]. Available from: https://www.sanofi.com/en/media-room/press-releases/2020/2020-07-02-22-30-00
   Google Scholar
• Sylvant® (siltuximab). Published online 2019.
   Google Scholar
• Nikanjam M, Yang J, Capparelli EV. Population pharmacokinetics of siltuximab: impact of disease state. Cancer Chemother Pharmacol. 2019;84(5):993–1001.
   PubMed Web of Science ®Google Scholar
• Gritti G, Raimondi F, Ripamonti D, et al. IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study. medRxiv. Published online 2020 Jan 1.
   Google Scholar
• Perrone F, Piccirillo MC, Ascierto PA, et al. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med.2020 Oct 21;18(1):405
   Google Scholar
• American Society of Health-System Pharmacists. Drug shortages list. [cited 2020 May 18]. Available from: https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortages-List?page=CurrentShortages&loginreturnUrl=SSOCheckOnly
   Google Scholar
• Thomas SK, Suvorov A, Noens L, et al. Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemother Pharmacol. 2014;73(1):35–42.
   PubMed Web of Science ®Google Scholar
• Grange S, Schmitt C, Banken L, et al. Thorough QT/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects. Int J Clin Pharmacol Ther. 2011;49(11):648–655.
   PubMed Web of Science ®Google Scholar
• Kewan T, Covut F, Al–Jaghbeer MJ, et al. Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. EClinicalMedicine. Published online 2020 June;24:100418.
   PubMedGoogle Scholar
• Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–e331.
   PubMedGoogle Scholar
• De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020;2(8):e465–e473.
   PubMedGoogle Scholar
• Roche. Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia. [ Published 2020 Sep 18; cited 2020 Oct 7]. Available from: https://www.roche.com/media/releases/med-cor-2020-09-18.htm
   Google Scholar